prostate cancer
Janssen sees promising PRO data for prostate cancer therapy
May 27, 2021Janssen, prostate cancer
Janssen has announced patient-reported outcomes (PRO) data from the pre-specified final analysis of their Phase III TITAN study in patients …
Astellas prostate cancer drug gets third approval from MHRA
May 12, 2021Research and Development Astellas, MHRA, cancer research, cancer treatment, pharma, pharma news, prostate cancer
The MHRA has approved Astellas Pharma’s XTANDI (enzalutamide) drug for the treatment of a third form of prostate cancer, making …
AstraZeneca to collaborate with Alchemab on prostate cancer research
May 6, 2021AstraZeneca, prostate cancer
AstraZeneca have announced a new collaboration with Cambridge-based biotech company Alchemab, with the aim of accelerating prostate cancer research. Alchemab …
Bayer’s Nubeqa combo approved in Europe for non-metastatic castration-resistant prostate cancer
March 31, 2020Manufacturing and Production, Research and Development Bayer, Cancer, Europe, Nubeqa, prostate cancer
The European Commission has given the green light to Bayer’s non-steroidal androgen receptor inhibitor Nubeqa (darolutamide), jointly developed with Orion, …
Prostate Cancer becomes most commonly diagnosed cancer in England
January 28, 2020Manufacturing and Production Cancer, Cancer diagnoses, NHS England, breast cancer, prostate cancer
Prostate cancer has overtaken breast cancer to be the most commonly diagnosed cancer for the first time in England, latest …
NHS Scotland recommends Janssen’s Zytiga combo for newly diagnosed prostate cancer
January 13, 2020Sales and Marketing Cancer, NHS, Scotland, nhs scotland, prostate cancer
Janssen’s Zytiga (abiraterone acetate) has just been approved by the Scottish Medicines Consortium (SMC), meaning that male patients on the …
Largest drop ever in US cancer mortality rates, new study shows
January 9, 2020Business Services Cancer, brain cancer, lung cancer, prostate cancer
The overall cancer mortality rate in the US fell by 2.2% from 2016 to 2017, the largest ever annual decline …
AstraZeneca sells Amrimidx and Casodex European rights to Juvisé Pharmaceuticals
December 20, 2019Medical Communications AstraZeneca, Cancer, Juvise, breast cancer, prostate cancer
AstraZeneca has announced that it has agreed to sell the rights to Arimidex (anastrozole) and Casodex (bicalutamide) in Europe, as …
FDA approves Pfizer and Astellas Pharma’s prostate cancer drug
December 17, 2019Manufacturing and Production Astellas Pharma, Cancer, FDA, Pfizer, Xtandi, prostate cancer
The FDA has approved Pfizer and Astellas Pharma’s Xtandi (enzalutamide) to treat patients with a type of prostate cancer. The …
Prostate Cancer ‘super responders’ could live for two more years on Keytruda
November 28, 2019Research and Development Cancer, immunotherapy, keytruda, oncology, prostate cancer
Men with advanced prostate cancer, who have exhausted all treatment options, could use the immunotherapy Keytruda (pembrolizumab) to live for …
Sanofi’s Jevtana doubles progression-free survival in metastatic castration-resistant prostate cancer
October 1, 2019Manufacturing and Production, Research and Development ESMO 2019, Jevtana, Sanofi, pharma, prostate cancer
Sanofi was present at the 2019 European Society of Medical Oncology (ESMO) Congress in Barcelona this year to reveal new …
FDA expands Janssen’s Erleada label to cover metastatic castration-sensitive prostate cancer
September 19, 2019Sales and Marketing Cancer, Erleada, FDA, Janssen, pharma, prostate cancer
Janssen has announced that the FDA has expanded the label of its androgen receptor inhibitor Erleada (apalutamide) to include the …
AstraZeneca’s Lynparza meets primary endpoint in Phase 3 prostate cancer trial
August 7, 2019Research and Development Lynpraza, PARP inhibitor, lynparza, pharma, prostate cancer
AstraZeneca’s PARP inhibitor Lynparza was successful in improving progression free survival in a Phase 3 trial of patients with metastatic …
Bayer and Orion’s Nubeqa secures FDA approval in non-metastatic castration-resistant prostate cancer
July 31, 2019Research and Development, Sales and Marketing Bayer, Cancer, Nubeqa, orion, pharma, prostate cancer
The FDA has awarded approval under its Priority Review pathway to Nubeqa (darolutamide) for the treatment of non-metastatic castration-resistant prostate …
New urine test can diagnose and offer prognosis for prostate cancer
July 8, 2019Sales and Marketing Cancer, oncology, pharma, prostate cancer, urine test
A new urine test can diagnose cases of aggressive prostate cancer more quickly than invasive biopsies. The test can also …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
